An innovative approach in the treatment of nodular adenomyosis

Introduction. The necessity to improve methods of adenomyosis treatment is determined not only by its high prevalence, which reaches 40 % among women reproductive age, but also association with infertility unclear genesis. disease significantly reduces the quality life. Objective. To optimize outcomes after surgical nodular and prevent recurrence. Materials Methods. A cohort prospective comparative study examined efficacy therapy dienogestam laparoscopic removal nodules temporary uterine artery occlusion balloon internal iliac arteries. included 25 who underwent organ-preserving for from January 1, 2020 2022. Inclusion criteria: age 22–45 years, mean 32 ± 4.5; organ preserving adenomyosis, no contraindications hormone therapy, informed voluntary consent patient participate in study. Results. use Dientogest at a dose 2 mg/day continuous regimen 6 months was shown transform intensity pain syndrome insignificant, absence recurrent 24 follow-up. Conclusions. comprehensive nodule drug dienogestam, permitted achievement function 40% patients. choice method depends primarily on plans patient, size location nodules, long-term results depend antiretroviral therapy.